Saturday 17 October 2026
Export ADTX’s income statement to Excel — free account
Aditxt, Inc.
ADTX Healthcare Biotechnology
Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024. In the quarter to March 2026, revenue grew 1,120.0%, EPS grew 99.6% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.00
0.00
NaN
Follow ADTX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 790,819,176,448.00 | 250,426,081,280.00 | 9,763,200,000.00 | 798,873,856.00 | 1,086,156.00 | 175.61 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 4,676,572,938,240.00 | 3,285,316,796,416.00 | 288,014,401,536.00 | 18,647,711,744.00 | 1,547,467,264.00 | 1,385,154.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 43 | 58 | 61 | 47 | 26 | 26 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 1 | 1 | 0 | 0 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 25.81 | 17.88 | (17.31) | (368.28) | 9.38 | |||||
| EBT | — | 0 | (6) | (6) | (9) | (46) | (28) | (32) | (35) | (43) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | (44,163.24) | (2,961.33) | (5,020.23) | (26,134.40) | (1,337,093.75) | |||||
| Net income | — | 0 | (6) | (6) | (9) | (46) | (28) | (32) | (35) | (43) | |||||
| Depreciation | — | — | — | — | 0 | 2 | 2 | 3 | 4 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 20.12 | 0.00 | 0.00 | 2.29 | ||||
| Earnings | — | (2.06) | (2,199.80) | (1.52) | (1.33) | (121.45) | (596.30) | (999,999,999.00) | (3,062.51) | (31,184.59) | |||||
| Cash flow | — | 0.00 | (148.58) | (0.12) | (1.05) | (58.35) | (482.59) | 0.00 | 0.00 | (18,348.86) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | (0.02) | (2.66) | (7.91) | 0.00 | 0.00 | (9.79) | |||||
| Free cash flow | — | 0.00 | (148.58) | (0.12) | (1.07) | (61.01) | (490.50) | 0.00 | 0.00 | (18,358.64) | |||||
| Book value | — | (0.58) | (591.04) | (0.74) | 1.60 | 26.67 | 112.20 | 0.00 | 0.00 | 2,824.07 | |||||
| Shares, m | — | 0 | 0 | 4 | 7 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | 0.00 | 766,584,229.03 | 0.00 | 0.00 | 81.45 | |||||
| P/B | — | — | — | — | — | 9,812,529,937.34 | 137,479,533.38 | 0.00 | 0.00 | 0.06 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | 766,584,227.47 | 1.89 | 3.61 | (525.68) | |||||
| EV/FCF | — | — | — | — | — | (4,288,650,881.97) | (31,449,384.78) | (0.06) | (0.03) | 0.06 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | 0 | (7) | (22) | (22) | (19) | (17) | (26) | ||||
| Capex | — | — | — | — | 0 | (1) | 0 | 0 | — | 0 | |||||
| Free cash flow | — | — | 0 | 0 | (7) | (23) | (23) | (19) | (17) | (26) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | (2) | (3) | 10 | 6 | 1 | (19) | (21) | (8) | ||||
| Total debt | — | — | 0 | 0 | 1 | 5 | 3 | — | — | — | |||||
| Net debt | — | 0 | 0 | 0 | (11) | (8) | (3) | 0 | (1) | (3) | |||||
| Shareholders’ equity | — | 0 | (2) | (3) | 11 | 10 | 5 | 16 | 1 | 4 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (302.77) | (9,834.40) | (4,872.66) | (138.41) | (310.94) | (202.11) | (118.24) | (105.19) | (177.15) | ||||
| ROIC | — | 0.00 | 0.00 | 0.00 | (1,085.79) | (1,135.24) | (653.28) | (102.13) | (6,739.48) | (1,619.88) | |||||
| ROE | — | 26.68 | 712.66 | 265.57 | (224.26) | (436.66) | (359.88) | (307.73) | (470.92) | (1,708.68) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 2 Oct 2026
Charts ten years each
Aditxt, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PCSA Heatwurx Inc. | $4.7M | 1.6× | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | Compare |
| DRMA Dermata Therapeutics, Inc. | $4.5M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ENLV Enlivex Ltd. | $4.5M | 0.0× | — | — | n/m | +35.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCNA NuCana PLC Sponsored ADR | $4.4M | — (loss-making) | — | — | n/m | +55.66% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | |
| AZTR Azitra, Inc. | $4.3M | 1.0× | — (loss-making) | −93.38% (below 0%: shrinking) | n/m | −19.55% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LIMN Liminatus Pharma Inc. | $4.3M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | Compare |
| LNAI Lunai Bioworks Inc. | $4.2M | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | Compare |
| JUNS Jupiter Neurosciences, Inc. | $4.1M | — (loss-making) | — | — | n/m | −177.06% (below 0%: shrinking) | 87.19% | (11,334.30%) | Compare |
| Median of peers | $4.4M | 1.0× | — | — | — | +15.14% | 0.00% | 0.00% |
Aditxt, Inc. (ADTX) key facts
- Concern: Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024.
- Aditxt, Inc. (ADTX) is a Biotechnology company in the Healthcare sector.
- Return on equity was −1,708.7% and debt-to-equity 0.00.
- Its Altman Z-score is −22.29 (distress zone) for fiscal 2025.